5 Nov 2014 07:00
5 November 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces that two U.S. patents have been granted by the United States Patent and Trademark Office that significantly strengthen the Company's current product portfolio and new product initiatives.
The first patent, US 8,871,278 (filed on March 19, 2012) covers the stabilisation of hypochlorous acid, particularly at high concentrations, in a variety of product formulations. The second patent, US 8,877,257 (filed on May 28, 2010) covers the use of PuriCore's unique hypochlorous acid formulation for the prevention and treatment of conditions characterised by infection and/or inflammation.
The inventions protected by these two patents represent a significant breakthrough. High concentrations of hypochlorous acid are difficult to stabilise and maintain with consistency in a bottled format, yet these high concentrations equate to greater anti-microbial and anti-inflammatory efficacy in healthcare applications. Stabilisation is also a significant factor in product shelf life, important in the healthcare supply chain and in the Company's targeted applications including infection control, inflammatory skin disease (e.g. atopic dermatitis) and, skin and wound infections, for both human and animal health.
These patents add to PuriCore's extensive intellectual property portfolio, which includes 35 granted patents (10 U.S. and 25 foreign) and 42 pending patents (both U.S. and foreign).
Michael Ashton, Chief Executive Officer of PuriCore, said:
"We believe that our hypochlorous acid product offerings are unique in their anti-microbial efficacy and benign safety profile. In particular, PuriCore's products are safe for use on skin and are non-harmful to the environment. The grant of these patents provides a key competitive advantage for the Company, particularly as we look to expand our bottled, consumable products and as we develop new products in the infection control, dermatology, and wound care arenas."
Enquiries:
FTI Consulting | +44 203 727 1000 |
Mo Noonan/Simon Conway | |
Victoria Foster Mitchell |
About PuriCore
PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in a well-established core business and emerging sectors of two broad markets: Food & Agriculture and Health Sciences. In the Food & Agriculture market, PuriCore's portfolio is used by thousands of US supermarket retailers, including three of the top-five, to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In the Health Sciences market, PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. PuriCore is headquartered in Malvern, Pennsylvania. To receive additional information on PuriCore, visit www.puricore.com.